2022 Midyear Review: Non–Small-Cell Lung Cancer

We are pleased to provide highlights of important and potentially practice-changing developments in immunotherapy of non–small-cell lung cancer (NSCLC) presented at the 2022 annual meetings of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). In this print supplement, we will summarize pivotal clinical data that were presented on immune checkpoint inhibitor therapy of NSCLC at both of these key meetings.

A total of 25 data presentations from AACR 2022 and ASCO 2022 are summarized in this resource. We hope that the information reviewed here can be applied to clinical practice and offers valuable insights into the important progress that is being made in the care of patients with NSCLC.